Table 4. Patient charateristics according to BCR–ABL subtype in patients with Ph+ALL who received HSCT in their first CR following imatinib-based therapy.
| Minor BCR–ABL (%) | Major BCR–ABL (%) | P | |
|---|---|---|---|
| No. of transplantations | 42 | 18 | |
| Median days from diagnosis to HSCT (range) | 149 (84–322) | 193 (67–512) | 0.090 |
| Conditioning regimen | 0.658 | ||
| Myeloablative | 37 (88) | 17 (94) | |
| Reduced intensity | 5 (12) | 1 (6) | |
| MRD status before HSCT (3 subjects unknown) | 1.000 | ||
| Positive | 13 (32) | 5 (29) | |
| Negative | 27 (68) | 12 (70) | |
| HCT-CI (7 subjects unknown) | 0.400 | ||
| 0 | 24 (67) | 12 (70) | |
| 1 | 8 (22) | 5 (30) | |
| 2– | 4 (11) | ||
| Cause of death | |||
| Leukemia relapse | 4 (10) | 2 (11) | 1.000 |
| Trasnplant related | 5 (12) | 8 (44) | 0.013 |
| Graft failure | 1 (2) | 4 (22) | |
| Infection | 1 (2) | 2 (11) | |
| cGVHD | 1 (2) | 1 (5) | |
| BO | 2 (5) | ||
| Others | 1 (5) | ||
Abbreviations: BO, bronchiolitis obliterans; CR, complete remission; cGVHD, chronic graft-versus-host disease; HCT-CI, hematopoietic cell transplantation (HCT)-specific comorbidity index; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; Ph+ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia.